Flaim S F, Stranieri M T, Gill A, Carson J R, Brannan M D
Department of Biological, McNeil Pharmaceutical, Spring House, Pennsylvania.
J Cardiovasc Pharmacol. 1988 Apr;11(4):489-500. doi: 10.1097/00005344-198804000-00017.
The purpose of this study was to characterize the cardiocirculatory effects of McN-5691 in the conscious spontaneously hypertensive rat (SHR) and in age matched Wistar-Kyoto (WKY) control rats. Animals were instrumented under halothane anesthesia for right atrial, left ventricular arterial, and venous pressure recordings. The radioactive microsphere technique was used to estimate regional blood flow and cardiac output before (control) and during intravenous (i.v.) infusion of either McN-5691 at three dosage levels (0.3, 1.0, 3.0 mg/kg), or vehicle (VH) at an infusion rate of 0.0408 ml/min. The predominant hemodynamic effect of McN-5691 (cumulative dose = 0.3-4.3 mg/kg i.v.) in conscious SHR was dose-related reduction in mean arterial pressure with normalization occurring at a cumulative dose of 1.3 mg/kg i.v. The antihypertensive effect of McN-5691 was accompanied by reductions in left ventricular peak systolic pressure (cumulative dose = 1.0-4.3 mg/kg i.v.), arterial pressure-rate product (1.3-4.3 mg/kg i.v.), and systemic vascular resistance (4.3 mg/kg i.v.). McN-5691 had no statistically significant effect on heart rate or cardiac contractility as measured by dP/dt/peak left ventricular pressure. The predominant peripheral vascular effects of McN-5691 were increases in skeletal muscle blood flow (4.3 mg/kg i.v.) and reductions in skeletal muscle (1.3-4.3 mg/kg i.v.), renal (1.3-4.3 mg/kg i.v.), gastrointestinal (4.3 mg/kg i.v.), and coronary (1.3-4.3 mg/kg i.v.) vascular resistances. Despite the fall in renal vascular resistance, renal blood flow was not changed by McN-5691. McN-5691 did not have major effects on other regions of the peripheral circulation. Thus, McN-5691 is an antihypertensive agent as defined by its ability to normalize blood pressure in the SHR, and the hemodynamic mechanism leading to this effect is reduction in peripheral vascular resistance. This antihypertensive effect is not accompanied by reflex tachycardia and is not associated with negative inotropic activity or detrimental peripheral circulatory changes in the conscious SHR.
本研究的目的是描述McN - 5691对清醒自发性高血压大鼠(SHR)以及年龄匹配的Wistar - Kyoto(WKY)对照大鼠心脏循环系统的影响。在氟烷麻醉下对动物进行仪器植入,以记录右心房、左心室动脉和静脉压力。采用放射性微球技术在静脉输注三种剂量水平(0.3、1.0、3.0 mg/kg)的McN - 5691或赋形剂(VH)(输注速率为0.0408 ml/min)之前(对照)和期间估计局部血流量和心输出量。McN - 5691(累积剂量 = 0.3 - 4.3 mg/kg静脉注射)对清醒SHR的主要血流动力学作用是平均动脉压呈剂量相关下降,累积剂量为1.3 mg/kg静脉注射时血压恢复正常。McN - 5691的降压作用伴随着左心室收缩压峰值下降(累积剂量 = 1.0 - 4.3 mg/kg静脉注射)、动脉压 - 心率乘积下降(1.3 - 4.3 mg/kg静脉注射)和全身血管阻力下降(4.3 mg/kg静脉注射)。McN - 5691对心率或通过左心室压力峰值dP/dt测量的心脏收缩力没有统计学上的显著影响。McN - 5691主要的外周血管作用是骨骼肌血流量增加(4.3 mg/kg静脉注射)以及骨骼肌(1.3 - 4.3 mg/kg静脉注射)、肾(1.3 - 4.3 mg/kg静脉注射)、胃肠道(4.3 mg/kg静脉注射)和冠状动脉(1.3 - 4.3 mg/kg静脉注射)血管阻力降低。尽管肾血管阻力下降,但McN - 5691并未改变肾血流量。McN - 5691对周围循环的其他区域没有重大影响。因此,McN - 5691因其使SHR血压恢复正常的能力而被定义为一种降压药,导致这种作用的血流动力学机制是外周血管阻力降低。这种降压作用不伴有反射性心动过速,且与清醒SHR的负性肌力活性或有害的外周循环变化无关。